This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
The molecular glue wave that first began years ago is still swelling, with Eli L...
Nxera Pharma has sold the Asia-Pacific rights to its phase 3 autoimmune drug to ...
Vir Biotechnology may be pushing ahead with its combination therapy in hepatitis...
The Department of Health and Human Services is re-evaluating a $590 million cont...
Teleflex announced plans to split into two companies—and is setting up one scion...
Kallyope has slipped out results from a phase 2 trial of its obesity candidates,...
Vertex has backed out of its in vivo gene editing collaboration with Verve Thera...
“While we remain confident in our zerlasiran program for high Lp(a), we will onl...
Even as President Donald Trump wages a very public fight against diversity, equi...
Clinical trial matchmaker myTomorrows has struck up a partnership with personal ...
The assets from Fresenius’ Spectra Laboratories subsidiary include water purific...
Kestra's vest-like Assure cardioverter defibrillators have been worn by more tha...
Alopexx is forging ahead with long-gestating plans to go public, updating IPO pa...
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 mil...
Eikon Therapeutics is no stranger to eye-catching funding rounds, and the cancer...
With the latest hopes of licensing its hypertension drug Tryvio falling through,...
AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting ...
Kiniksa Pharmaceuticals is stopping development of a midphase autoimmune asset a...
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to...
The deal will see HBM Alpha Therapeutics, which was formed around Harbour’s anti...
The deal will see HBM Alpha Therapeutics, which was formed around Harbour’s anti...
In addition to the previously disclosed two deaths, the FDA said in its Feb. 21 ...
Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calcul...
Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrom...